Middle East & Africa DNA Sequencing Market Research Report – Segmented By Product & Services, Technology, Workflow, Application, End User, and Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis on Size, Share, Trends & Growth Forecast (2024 to 2029)

Updated On: January, 2024
ID: 11718
Pages: 90

MEA DNA Sequencing Market Size (2023 to 2028)

The Middle East & Africa DNA sequencing market size is estimated to grow at a moderate CAGR during the forecast period.

DNA sequencing has applications in the research of animal and plant breeding. Selecting the best animals for next-generation breeding requires a thorough understanding of livestock genetics. Genomic technologies are fully established inbreeding and are becoming increasingly efficient due to innovations and technological advancements. The field of modern agriculture has instituted techniques such as genome sequencing, genome-wide association, genotyping, and genetic markers. In addition, genome sequencing has achieved satisfactory success in rearing beef and dairy cattle with improved properties in traits such as milk production, meat quality, feed efficiency, and health.


Factors such as constant technological advancements in sequencing methods, advancements in bioinformatics, increasing applications of NGS (Next-Generation Sequencing) and WGS (Whole-Genome Sequencing), increasing prevalence of viral diseases such as SARS and COVID-19, increasing cancer cases globally, and increasing spending on research and development are expected to drive the MEA DNA sequencing market. Other factors such as applications in cancer research, biomarker discovery, personalized medicine, genomic analysis, and forensic science are predicted to accelerate the MEA market for DNA sequencing market. Ongoing collaborations and partnerships among leading market players to launch new and innovative technologies have increased the general market demand for the DNA sequencing market in the MEA region.

High investment in research and development and acquisitions, mergers, and collaborations are the key strategies undertaken by companies operating in the MEA DNA sequencing market.


University R&D in developing countries depends mainly on external funding. Despite continued efforts by government and private organizations to fund research worldwide, several academic and research institutes face budget constraints when it comes to purchasing and using advanced equipment and technologies and resultant higher prices. As a result, the installation/expansion of advanced research facilities are hampered in developing countries' academic and research institutes. This is a major barrier to adopting technologies such as DNA sequencing in developing countries in Africa and parts of the Middle East region.

Impact of COVID-19 on the MEA DNA sequencing market:

The COVID-19 pandemic has had a positive impact on the market study as the demand for DNA sequencing technology in developing therapies and diagnostics increases.

Tests for the qualitative detection of SARS-CoV-2 nucleic acid in upper respiratory tract samples from individuals suspected of COVID-19. Therefore, due to the increase in research and development activities based on DNA sequencing in developing diagnostic tools or effective therapies for COVID-19, the market is expected to flourish at a significant growth rate.

Recently, researchers at the University of Birmingham developed a COVID-19 test that cuts the test time from 30 minutes to less than 5 minutes and shows accurate results. This method uses a DNA sequence (called a binder DNA) that identifies and binds the SARS-CoV-2 viral RNA and an enzyme that identifies the binder DNA and cuts a small section if the viral RNA exists. An exponential increase in COVID-19 cases has spurred demand for these technologies in large-scale rapid genomic sequencing projects to monitor the viral spread and guide future treatments. The aforementioned factor is boosting the demand for DNA sequencing the diagnosis of COVID-19.

This research report on the MEA DNA sequencing market has been segmented and sub-segmented into the following categories.

By Product & Services:

  • Consumables
  • Instruments
  • Services

By Technology:

  • Sanger Sequencing
  • Next-Generation Sequencing
  • Whole Genome Sequencing (WGS)
  • Whole Exome Sequencing (WES)
  • Targeted Sequencing & Resequencing
  • Third Generation DNA Sequencing  
  • Single-Molecule Real-Time Sequencing (SMRT)
  • Nanopore Sequencing

By Workflow:

  • Pre-sequencing
  • Sequencing
  • Data Analysis

By Application:

  • Oncology
  • Reproductive Health
  • Clinical Investigation
  • Agri genomics & Forensics
  • HLA Typing/Immune System Monitoring
  • Metagenomics, Epidemiology & Drug Development
  • Consumer Genomics
  • Others

By End-use:

  • Academic Research
  • Clinical Research
  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Other Users

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Geographically, among MEA, the Middle East region is expected to account for a significant share during the forecast period. The availability of decent healthcare infrastructure has enabled Middle East to gain a major share in the MEA DNA sequencing market. The presence of various government initiatives in the Middle East supports research in drug development and treatment of cancer and other diseases.

The African DNA sequencing market is forecasted to register a moderate CAGR between 2023 and 2028. The strategic initiatives undertaken by international companies to expand their presence due to the high customer base are expected to create many market growth opportunities in the region. Still, a slower growth rate is expected compared to other developed countries due to less awareness.


Companies such as Agilent Technologies, Inc., Abbott Laboratories, Danaher Corporation (Beckman Coulter, Inc.), F. Hoffmann-La Roche Ltd, Illumina, Inc., LI-COR Biosciences, Inc., Pacific Biosciences of California, Inc., SIEMENS AG, PerkinElmer Inc., and Thermo Fisher Scientific, Inc. are playing a leading role in the MEA DNA sequencing market.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1200

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample